Development of serum-free differentiation medium towards CD1a subset of dendritic cells

      Dendritic cells have garnered interest in recent years due to their ability to combat cancer. These dendritic cells once programmed can generate cancer vaccines and recruit the aid of T-cells which will later attack cancerous cells. However dendritic cells are not readily available in large numbers. In many cases, dendritic cells are either isolated or derived from monocytes. Currently monocyte derivation is the preferred method due to the availability of monocyte and its obtainability from an autologous source. Further research has shown the media to be a key component in deriving the dendritic cells into the proper phenotype for cancer vaccines. Irvine Scientific (IS) has developed a serum free media that is specifically for deriving dendritic cells from monocytes. Through rational design of its formulation, this IS media favors derivation of the CD1a positive subset of dendritic cells which are now to activate the immunogenic response against cancer by T-cells. Comparison data between competitor's media and its serum added counterpart show higher amounts of the CD1a positive subset of dendritic cells produced with IS media. Functionality data is generated to reflect this CD1a positive DC phenotype. In this study, we demonstrate how the serum-free formula of IS media can provide the proper phenotypic subset of dendritic cells with cancer vaccine capability.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect